How to Start Lamotrigine Safely in Bipolar Disorder
How should clinicians initiate and monitor lamotrigine in bipolar disorder based on the dosing and safety procedures used in this study?
Lamotrigine is used in bipolar disorder maintenance treatment, but safe initiation matters because rash and serious skin reactions can occur. This article describes the titration schedules used in routine care and reports the adverse drug reaction profile observed over 1 year.
-
Register or review the patient early after starting lamotrigine
In the study, patients were prospectively registered within 14 days of starting lamotrigine treatment and then followed for 1 year. In practice, early review after initiation helps anchor the maintenance plan and establishes a baseline for later recurrence and adverse event monitoring.
-
Use the standard 6-week monotherapy titration
When lamotrigine was used as monotherapy, the study followed a 6-week escalation to a target dose of 200 mg/d. The schedule was weeks 1-2 at 25 mg/d, weeks 3-4 at 50 mg/d, week 5 at 100 mg/d, and week 6 at 200 mg/d.
-
Halve the schedule when used with valproate
When lamotrigine was used adjunctively with valproate, both the starting and target doses were halved. The schedule was weeks 1-2 at 25 mg every other day, weeks 3-4 at 25 mg/d, week 5 at 50 mg/d, and week 6 at 100 mg/d.
-
Double the schedule when used with carbamazepine
When lamotrigine was used adjunctively with carbamazepine, both the starting and target doses were doubled. The schedule was weeks 1-2 at 50 mg/d, weeks 3-4 at 100 mg/d, week 5 at 200 mg/d, and week 6 at 300 mg/d.
-
Prescribe according to the package insert
Investigators were requested to prescribe lamotrigine in accordance with the Japanese package insert, and the discussion emphasizes that clinicians should follow the dosage and administration in the package insert when using lamotrigine. The authors note that lamotrigine is known to cause severe skin rashes and that the risk becomes high when prescribed beyond the defined dosage and administration.
-
Ask about recurrence and adverse events at every visit
At each visit after lamotrigine initiation, patients in the study were asked about recurrence or relapse of mood episodes and all adverse events. If a mood episode recurred, clinicians recorded whether it was manic, hypomanic, mixed, or major depressive, along with onset and remission timing; for adverse events, they recorded the event name, onset date, outcome, seriousness, and causal relationship to lamotrigine.
-
Pay particular attention to rash and serious skin disorders
Rash was the most frequently reported adverse drug reaction in both bipolar I and bipolar II disorder. Skin disorders occurred in 11.5% of both groups, and serious skin disorders occurred in 0.5% of bipolar I patients and 1.5% of bipolar II patients, including Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome, erythema multiforme, and drug eruption.
Clinical Considerations
- The study reported no increasing trend in serious skin disorders among patients with rapid titration and or high starting dose, but the authors still state that clinicians should follow the package-insert dosing because severe skin rash risk is known to increase beyond recommended dosing and administration.
- This was an observational postmarketing surveillance study rather than a randomized safety trial.
- No significant overall safety difference was detected between bipolar I and bipolar II disorder, with adverse drug reactions in 22.0% and 21.8%, respectively.
Bottom Line
When starting lamotrigine in bipolar disorder, use the package-insert titration schedule, adjust for valproate or carbamazepine, and monitor closely for rash and other skin reactions at every visit.
